Integra LifeSciences
IART
189 hedge funds and large institutions have $1.83B invested in Integra LifeSciences in 2015 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 33 increasing their positions, 122 reducing their positions, and 30 closing their positions.
13% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 30
2% more funds holding
Funds holding: 186 → 189 (+3)
1% more capital invested
Capital invested by funds: $1.82B → $1.83B (+$12M)
50% less call options, than puts
Call options by funds: $71K | Put options by funds: $141K
73% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 122
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$35.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.4M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$19.1M |
| 4 |
FA
Friess Associates
Greenville,
Delaware
|
+$17.5M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.9M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$28.7M |
| 3 |
HM
HealthCor Management
New York
|
-$26M |
| 4 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
-$15.3M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$13.2M |
IART Hedge Fund Activity: Q3 2015 in Review
189 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2015, worth a combined $1.83B — up 0.66% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IART positions and 30 closed out — a net gain of 4 holders — while 33 added to existing stakes and 122 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $35.1M. The largest seller was Fidelity Investments, cutting an estimated $35.9M.
- 189 institutional investors held Integra LifeSciences (IART) as of Q3 2015, up from 186 in Q2 2015.
- Funds reported $1.83B of Integra LifeSciences stock for Q3 2015, up 0.66% quarter-over-quarter.
- 34 funds opened new Integra LifeSciences positions in Q3 2015 and 30 closed out, a net change of +4 holders.
- The largest Integra LifeSciences buyer in Q3 2015 was Goldman Sachs, an estimated $35.1M added.
- The largest Integra LifeSciences seller in Q3 2015 was Fidelity Investments, an estimated $35.9M sold.
Based on aggregated 13F filings for Q3 2015.